{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:05:48Z","timestamp":1793995548699,"version":"4.8.0"},"reference-count":367,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"LSD"},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.neuropharm.2019.107704","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:09:03Z","timestamp":1562670543000},"page":"107704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":359,"special_numbering":"C","title":["Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-0806","authenticated-orcid":false,"given":"Stephen J.","family":"Kaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Natesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.107704_bib1","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1523\/JNEUROSCI.2097-04.2005","article-title":"Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457","volume":"25","author":"Aalto","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.9.1.1","article-title":"The role of serotonin in the pathophysiology and treatment of schizophrenia","volume":"9","author":"Abi-Dargham","year":"1997","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib5","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2019.107704_bib6","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia","volume":"22","author":"Abi-Dargham","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.biopsych.2008.12.007","article-title":"Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects","volume":"65","author":"Abi-Dargham","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib8","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/0269881111409265","article-title":"Increased prefrontal cortical D1 receptors in drug na\u00efve patients with schizophrenia: a PET study with [11C]NNC112","volume":"26","author":"Abi-Dargham","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainres.2003.09.082","article-title":"The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release","volume":"1003","author":"Aihara","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1176\/ajp.156.9.1358","article-title":"Memory impairment in schizophrenia: a meta-analysis","volume":"156","author":"Aleman","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib11","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib12","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/schbul\/sbx021.037","article-title":"18. Evenamide, a putative antipsychotic, targets abnormal electrical activity and glutamatergic abnormalities to improve psychotic symptoms in patients with schizophrenia: results from a phase II, placebo-controlled trial","volume":"43","author":"Anand","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib13","first-page":"943","article-title":"Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the tower of London","volume":"49","author":"Andreasen","year":"1992","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00427592","article-title":"Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects","volume":"67","author":"Angrist","year":"1980","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \"Seroquel\" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mp.2017.16","article-title":"The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment","volume":"22","author":"Ashok","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euroneuro.2006.07.001","article-title":"Striatal D2 receptor occupancy in bipolar patients treated with olanzapine","volume":"17","author":"Attarbaschi","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/026988110401800304","article-title":"A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment","volume":"18","author":"Bantick","year":"2004","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/syn.20156","article-title":"The effect of a 5-HT1A receptor agonist on striatal dopamine release","volume":"57","author":"Bantick","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2019.107704_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0920-9964(96)00122-3","article-title":"Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics","volume":"24","author":"Beasley","year":"1997","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","article-title":"Dopamine receptors - IUPHAR review 13","volume":"172","author":"Beaulieu","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/31709","article-title":"Modulation of AMPA receptor unitary conductance by synaptic activity","volume":"393","author":"Benke","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/026988119801200310","article-title":"Monoaminergic synapses and schizophrenia: 45 years of neuroleptics","volume":"12","author":"Bennett","year":"1998","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib27","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1523\/JNEUROSCI.4975-05.2006","article-title":"Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain","volume":"26","author":"Bertolino","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/361031a0","article-title":"A synaptic model of memory: long-term potentiation in the hippocampus","volume":"361","author":"Bliss","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1176\/appi.ajp.2015.14101358","article-title":"Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study","volume":"173","author":"Bloomfield","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neuropharm.2017.02.024","article-title":"Kv3.1\/Kv3.2 channel positive modulators enable faster activating kinetics and increase firing frequency in fast-spiking GABAergic interneurons","volume":"118","author":"Boddum","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0022-3565(25)11335-9","article-title":"Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells","volume":"260","author":"Bolden","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0028-3908(97)00049-X","article-title":"RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist","volume":"36","author":"Bonhaus","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbt085","article-title":"Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?","volume":"40","author":"Bora","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib35","article-title":"Neural responsivity to food cues in patients with unmedicated first-episode PsychosisNeural responsivity to food cues in patients with unmedicated first-episode PsychosisNeural responsivity to food cues in patients with unmedicated first-episode psychosis","volume":"2","author":"Borgan","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neuropharm.2019.107704_bib36","article-title":"Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis","author":"Bossong","year":"2018","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-2999(99)00916-4","article-title":"Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice","volume":"391","author":"Boulay","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1176\/ajp.116.8.744","article-title":"Reserpine as a therapeutic agent in schizophrenia","volume":"116","author":"Braun","year":"1960","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib39","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method","volume":"94","author":"Breier","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2019.107704_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.107704_bib41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0165-6147(97)01066-3","article-title":"Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist","volume":"18","author":"Bristow","year":"1997","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib42","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"Bugarski-Kirola","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1126\/science.847477","article-title":"Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain","volume":"196","author":"Burt","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.107704_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ana.410310404","article-title":"Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission","volume":"31","author":"Calabresi","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib47","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00213-016-4218-9","article-title":"Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness","volume":"233","author":"Calcia","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib48","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0021-9258(17)38065-1","article-title":"Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release","volume":"253","author":"Caron","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.107704_bib49","first-page":"25","article-title":"Pathophysiology of antipsychotic drug-induced movement disorders","volume":"65","author":"Casey","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib50","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1523\/JNEUROSCI.3296-15.2016","article-title":"Dynamic connectivity between brain networks supports working memory: relationships to dopamine release and schizophrenia","volume":"36","author":"Cassidy","year":"2016","journal-title":"J. Neurosci. : Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib51","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib52","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/0269881112444941","article-title":"Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment","volume":"26","author":"Chaudhry","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev.neuro.29.051605.112834","article-title":"Endocannabinoid-mediated synaptic plasticity in the CNS","volume":"29","author":"Chevaleyre","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.neuropharm.2019.107704_bib55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1176\/appi.ajp.2015.15020150","article-title":"Dysregulated ErbB4 splicing in schizophrenia: selective effects on parvalbumin expression","volume":"173","author":"Chung","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib56","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.neuropharm.2019.107704_bib57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12325-013-0004-9","article-title":"Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy","volume":"30","author":"Citrome","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib58","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/hbm.460010407","article-title":"Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI","volume":"1","author":"Cohen","year":"1994","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.neuropharm.2019.107704_bib60","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd1062","article-title":"Discovering risperidone: the LSD model of psychopathology","volume":"2","author":"Colpaert","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2019.107704_bib61","series-title":"Amphetamine Psychosis, Maudsley Monograph No. 5, 1958","author":"Connell","year":"1958"},{"key":"10.1016\/j.neuropharm.2019.107704_bib62","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.neuropharm.2019.107704_bib63","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.107704_bib64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.134.3.249","article-title":"Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings","volume":"134","author":"Crow","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib65","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/appi.ajp.2011.11010052","article-title":"Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features","volume":"168","author":"Curley","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib66","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1192\/bjp.185.3.196","article-title":"Stimulant psychosis: systematic review","volume":"185","author":"Curran","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib67","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib68","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: a review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.160.2.303","article-title":"Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study","volume":"160","author":"de Haan","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib70","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0026-895X(25)15148-1","article-title":"Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists","volume":"22","author":"De Lean","year":"1982","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib71","first-page":"123","article-title":"M-100907 (aventis)","volume":"2","author":"de Paulis","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2019.107704_bib72","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","article-title":"The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Deakin","year":"2018","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib73","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/endo-89-3-774","article-title":"Effects of drugs that modify brain monoamine concentrations on plasma gonadotropin and prolactin levels in the rat","volume":"89","author":"Donoso","year":"1971","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib74","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.biopsych.2017.12.019","article-title":"Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the Glycine transporter-1 inhibitor PF-03463275 in healthy and schizophrenia subjects","volume":"84","author":"D'Souza","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib75","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0026-895X(25)14305-8","article-title":"Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary","volume":"23","author":"Enjalbert","year":"1983","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib76","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/npp.2016.24","article-title":"Reduced labeling of parvalbumin neurons and perineuronal nets in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"41","author":"Enwright","year":"2016","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib77","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.93.10.5166","article-title":"Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter","volume":"93","author":"Erickson","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib78","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4088\/JCP.11r07324","article-title":"Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment","volume":"73","author":"Farahani","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs","volume":"45","author":"Farde","year":"1988","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib80","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib81","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib82","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.biopsych.2017.11.032","article-title":"Amphetamine-induced striatal dopamine release measured with an agonist radiotracer in schizophrenia","volume":"83","author":"Frankle","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.schres.2014.02.021","article-title":"Schizophrenia and bipolar disorder show both common and distinct changes in cortical interneuron markers","volume":"155","author":"Fung","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/mp.2009.108","article-title":"Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis","volume":"16","author":"Fusar-Poli","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib85","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib86","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00406-015-0590-4","article-title":"Neurobiological background of negative symptoms","volume":"265","author":"Galderisi","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib87","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/10673229409017120","article-title":"Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis","volume":"2","author":"Ganguli","year":"1994","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2007.03.011","article-title":"A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia","volume":"93","author":"George","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib90","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/npp.2011.76","article-title":"A novel alpha5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia","volume":"36","author":"Gill","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib91","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib92","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0269881116636120","article-title":"A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia","volume":"30","author":"Girgis","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib93","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/npp.2017.258","article-title":"A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia","volume":"43","author":"Girgis","year":"2018","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib94","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib95","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/mp.2013.152","article-title":"Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects","volume":"19","author":"Glausier","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib96","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1152\/jn.01122.2005","article-title":"Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABA A receptor alpha5 subunit-deficient mice","volume":"95","author":"Glykys","year":"2006","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib97","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1113\/jphysiol.2007.134460","article-title":"The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus","volume":"582","author":"Glykys","year":"2007","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib98","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1523\/JNEUROSCI.4751-07.2008","article-title":"Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?","volume":"28","author":"Glykys","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib99","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/YCO.0000000000000152","article-title":"Drug development in schizophrenia: are glutamatergic targets still worth aiming at?","volume":"28","author":"Goff","year":"2015","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.npp.1301444","article-title":"A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia","volume":"33","author":"Goff","year":"2007","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-004-1793-y","article-title":"Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction","volume":"174","author":"Goldman-Rakic","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib102","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","article-title":"The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO","volume":"66","author":"Graff-Guerrero","year":"2009","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib103","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib104","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/schbul\/sbm074","article-title":"Molecular targets for treating cognitive dysfunction in schizophrenia","volume":"33","author":"Gray","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2019.107704_bib105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.14074su1c.02","article-title":"Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia","volume":"77","author":"Green","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib106","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archpsyc.1972.01750200001001","article-title":"Dextroamphetamine: evaluation of psychomimetic properties in man","volume":"26","author":"Griffith","year":"1972","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib107","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0924-977X(95)00030-S","article-title":"The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches","volume":"5","author":"Griffon","year":"1995","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neubiorev.2017.01.029","article-title":"Altered reward anticipation: potential explanation for weight gain in schizophrenia?","volume":"75","author":"Grimm","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib109","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","article-title":"Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18 F] fallypride PET study","volume":"165","author":"Gr\u00fcnder","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib110","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archpsyc.57.11.1061","article-title":"Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study","volume":"57","author":"Guidotti","year":"2000","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib111","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","article-title":"Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons","volume":"20","author":"Gurevich","year":"1999","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib112","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","article-title":"Antipsychotic-related QTc prolongation, torsade de pointes and sudden death","volume":"62","author":"Haddad","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2019.107704_bib113","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2019.107704_bib114","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.npp.1300450","article-title":"Effects of nicotine on cognitive deficits in schizophrenia","volume":"29","author":"Harris","year":"2004","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib115","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1523\/JNEUROSCI.23-15-06315.2003","article-title":"Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia","volume":"23","author":"Hashimoto","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib116","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/appi.ajp.2007.07081223","article-title":"Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia","volume":"165","author":"Hashimoto","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib117","first-page":"1469","article-title":"Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications","author":"Heckman","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib118","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2018.02.007","article-title":"Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations","volume":"87","author":"Heckman","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib119","doi-asserted-by":"crossref","first-page":"aad3873","DOI":"10.1126\/science.aad3873","article-title":"Structure and organization of heteromeric AMPA-type glutamate receptors","volume":"352","author":"Herguedas","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.107704_bib120","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(95)91801-9","article-title":"Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients","volume":"346","author":"Hietala","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107704_bib121","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorthoj","year":"2017","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib122","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/mp.2016.180","article-title":"In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study","volume":"21","author":"Holmes","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib123","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III--the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.278","article-title":"Inflammation and the neural diathesis-stress hypothesis of schizophrenia","volume":"7","author":"Howes","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib125","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","article-title":"Schizophrenia: an integrated sociodevelopmental-cognitive model","volume":"383","author":"Howes","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107704_bib126","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1176\/appi.ajp.161.2.361","article-title":"A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance","volume":"161","author":"Howes","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib127","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.jcp.0000239791.91330.48","article-title":"The relationship between prolactin levels and glucose homeostasis in antipsychotic-treated schizophrenic patients","volume":"26","author":"Howes","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib128","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.2174\/138161209788957528","article-title":"Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging","volume":"15","author":"Howes","year":"2009","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2019.107704_bib129","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.2174\/138161209788957528","article-title":"Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging","volume":"15","author":"Howes","year":"2009","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2019.107704_bib130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/archgenpsychiatry.2008.514","article-title":"Elevated striatal dopamine function linked to prodromal signs of schizophrenia","volume":"66","author":"Howes","year":"2009","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib131","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/mp.2011.20","article-title":"Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study","volume":"16","author":"Howes","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib132","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1176\/appi.ajp.2011.11010160","article-title":"Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study","volume":"168","author":"Howes","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib133","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib134","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1093\/brain\/awt264","article-title":"Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study","volume":"136","author":"Howes","year":"2013","journal-title":"Brain : J. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21(st) century","volume":"29","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib136","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib137","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-011-2471-5","article-title":"Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo","volume":"220","author":"Humbert-Claude","year":"2012","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib138","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0028-3908(88)90134-7","article-title":"8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis","volume":"27","author":"Invernizzi","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib139","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.euroneuro.2004.10.001","article-title":"Histamine H1 receptors in schizophrenic patients measured by positron emission tomography","volume":"15","author":"Iwabuchi","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib141","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00491982","article-title":"Amphetamine psychosis and psychotic symptoms","volume":"65","author":"Janowsky","year":"1979","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib142","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2015.01.041","article-title":"A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy","volume":"164","author":"Jarskog","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib143","article-title":"Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy","volume":"7","author":"Jauhar","year":"2019","journal-title":"Int. J. Behav. Dev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib144","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamapsychiatry.2017.2943","article-title":"A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia","volume":"74","author":"Jauhar","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib145","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.270","article-title":"Regulation of dopaminergic function: an [(18)F]-DOPA PET apomorphine challenge study in humans","volume":"7","author":"Jauhar","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib146","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2215-0366(18)30268-2","article-title":"The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study","volume":"5","author":"Jauhar","year":"2018","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib147","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biopsych.2018.07.003","article-title":"The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study","volume":"85","author":"Jauhar","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib148","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/schbul\/sbs069","article-title":"Has an angel shown the way? Etiological and therapeutic implications of the PCP\/NMDA model of schizophrenia","volume":"38","author":"Javitt","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib149","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1476-5381.2009.00149.x","article-title":"Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases","volume":"157","author":"Jin","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib150","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/JCP.0b013e31818ba5d8","article-title":"Antipsychotic-induced hyperprolactinemia: a cross-sectional survey","volume":"28","author":"Johnsen","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib151","first-page":"1347","article-title":"5-HT2A deletion protects against Clozapine-induced hyperglycemia","author":"Joshi","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib152","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2016.07.013","article-title":"Individual negative symptoms and domains \u2013 relevance for assessment, pathomechanisms and treatment","volume":"186","author":"Kaiser","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib153","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1192\/bjp.bp.113.132308","article-title":"Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies","volume":"204","author":"Kambeitz","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib154","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib155","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib156","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuroscience.2006.09.026","article-title":"Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity","volume":"144","author":"Kanes","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.107704_bib157","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action","volume":"25","author":"Kapur","year":"2000","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib158","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s002130050277","article-title":"The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study","volume":"131","author":"Kapur","year":"1997","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib159","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib161","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib162","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1176\/appi.ajp.158.2.311","article-title":"Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib163","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib164","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00001504-200403000-00008","article-title":"The newer antipsychotics: underlying mechanisms and the new clinical realities","volume":"17","author":"Kapur","year":"2004","journal-title":"Curr. Opin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib165","series-title":"Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients","author":"Karlsson","year":"1995"},{"key":"10.1016\/j.neuropharm.2019.107704_bib166","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the catie trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib167","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0006-3223(00)00976-8","article-title":"Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia","volume":"48","author":"Kegeles","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib168","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/npp.2008.33","article-title":"Dose\u2013occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride","volume":"33","author":"Kegeles","year":"2008","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib169","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archgenpsychiatry.2010.10","article-title":"Increased synaptic dopamine function in associative regions of the striatum in schizophrenia","volume":"67","author":"Kegeles","year":"2010","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138161211795049624","article-title":"PDE10A inhibitors: novel therapeutic drugs for schizophrenia","volume":"17","author":"Kehler","year":"2011","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2019.107704_bib171","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.12m08271","article-title":"Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder","volume":"75","author":"Kemp","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib172","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the Cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2019.107704_bib173","article-title":"Ventral striatal hypoactivation is associated with apathy but not diminished expression in patients with schizophrenia","volume":"40","author":"Kirschner","year":"2015","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib174","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","article-title":"Secondary negative symptoms - a review of mechanisms, assessment and treatment","volume":"186","author":"Kirschner","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib175","first-page":"30","article-title":"Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: a meta-analysis of randomized placebo-controlled trials","volume":"48","author":"Kishi","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib176","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0925-4927(97)00023-1","article-title":"Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels","volume":"75","author":"Knable","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib177","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib178","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.schres.2011.06.007","article-title":"Hippocampal interneurons are abnormal in schizophrenia","volume":"131","author":"Konradi","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib179","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1186\/1744-859X-9-S1-S164","article-title":"Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole","volume":"l","author":"Kotorki","year":"2010","journal-title":"Ann. Gen. Psychiatr. Biomed. Cent."},{"key":"10.1016\/j.neuropharm.2019.107704_bib180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib181","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib182","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib183","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib184","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2019.107704_bib185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2017.07.037","article-title":"Hyperprolactinaemia in first episode psychosis - a longitudinal assessment","volume":"189","author":"Lally","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib186","first-page":"1182","article-title":"SPECT imaging of striatal dopamine release after amphetamine challenge","volume":"36","author":"Laruelle","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuropharm.2019.107704_bib187","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib188","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/npp.2013.111","article-title":"Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases","volume":"38","author":"Lasser","year":"2013","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib189","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/274897a0","article-title":"Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains","volume":"274","author":"Lee","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib190","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neuropharm.2014.02.007","article-title":"Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors","volume":"81","author":"Leo","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib191","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107704_bib192","first-page":"1535","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib193","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archpsyc.1984.01790160106014","article-title":"Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses","volume":"41","author":"Levy","year":"1984","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib194","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib195","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0165-0173(99)00042-9","article-title":"GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia","volume":"31","author":"Lewis","year":"2000","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib196","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0893-133X(02)00366-4","article-title":"Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET\/[11C]raclopride study in healthy men","volume":"27","author":"Leyton","year":"2002","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib197","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/acs.jmedchem.5b01751","article-title":"Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases","volume":"59","author":"Li","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.107704_bib198","first-page":"20","article-title":"Managing anticholinergic side effects","volume":"6","author":"Lieberman","year":"2004","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib199","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","article-title":"Provocative tests with psychostimulant drugs in schizophrenia","volume":"91","author":"Lieberman","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib200","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.107704_bib201","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/jpet.107.132647","article-title":"Trace amine-associated receptor 1 modulates dopaminergic activity","volume":"324","author":"Lindemann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib202","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev.neuro.20.1.125","article-title":"The role of vesicular transport proteins in synaptic transmission and neural degeneration","volume":"20","author":"Liu","year":"1997","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib203","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1172\/JCI93362","article-title":"The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C","volume":"127","author":"Lord","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107704_bib204","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00406-018-0970-7","article-title":"Cannabis and mental illness: a review","volume":"269","author":"Lowe","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2018.08.028","article-title":"A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia","volume":"204","author":"Macek","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib206","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0140-6736(80)92072-3","article-title":"DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS?","volume":"316","author":"Mackay","year":"1980","journal-title":"The Lancet"},{"key":"10.1016\/j.neuropharm.2019.107704_bib207","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib208","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev.neuro.25.112701.142758","article-title":"AMPA receptor trafficking and synaptic plasticity","volume":"25","author":"Malinow","year":"2002","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib209","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"164","author":"Mamo","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.31887\/DCNS.2006.8.1\/smarder","article-title":"The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia","volume":"8","author":"Marder","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib211","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107704_bib212","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II\/III studies","volume":"29","author":"Marder","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib213","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1523\/JNEUROSCI.4209-09.2010","article-title":"Alpha5GABAA receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory","volume":"30","author":"Martin","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib214","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tips.2006.03.008","article-title":"The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity","volume":"27","author":"Masaki","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib215","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/archgenpsychiatry.2012.934","article-title":"Neural correlates of weight gain with olanzapine","volume":"69","author":"Mathews","year":"2012","journal-title":"Arch. Gen. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2019.107704_bib216","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the Locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis","volume":"44","author":"McCutcheon","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.neuropharm.2019.107704_bib217","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from Biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib218","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib219","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib220","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.biopsych.2008.11.019","article-title":"Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia","volume":"65","author":"Mellios","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib221","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/schbul\/6.3.456","article-title":"Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies","volume":"6","author":"Meltzer","year":"1980","journal-title":"Schizophr. Bull."},{"issue":"Suppl. l","key":"10.1016\/j.neuropharm.2019.107704_bib222","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/BF00442554","article-title":"Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib223","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","author":"Meltzer","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib224","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib225","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","article-title":"Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg\/day, but does not enhance efficacy of haloperidol, 2mg\/day: comparison with reference dose risperidone, 6mg\/day","volume":"141","author":"Meltzer","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib226","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd2058","article-title":"Phosphodiesterases in the CNS: targets for drug development","volume":"5","author":"Menniti","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2019.107704_bib227","first-page":"323","article-title":"Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice","volume":"79","author":"Mercuri","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.107704_bib228","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/JCP.0b013e3182970490","article-title":"A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia","volume":"33","author":"Meskanen","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib229","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nn1438","article-title":"Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype","volume":"8","author":"Meyer-Lindenberg","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib230","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: progress and perspectives","volume":"15","author":"Millan","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2019.107704_bib231","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/npp.2016.211","article-title":"Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions","volume":"42","author":"Miller","year":"2017","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib232","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/npp.1994.31","article-title":"Effect of antipsychotic withdrawal on negative symptoms in schizophrenia","volume":"11","author":"Miller","year":"1994","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib233","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4088\/JCP.15l09920","article-title":"An open-label, pilot trial of adjunctive tocilizumab in schizophrenia","volume":"77","author":"Miller","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib234","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nature02440","article-title":"AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus","volume":"428","author":"Minokoshi","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib235","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib236","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/archgenpsychiatry.2009.91","article-title":"Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia","volume":"66","author":"Minzenberg","year":"2009","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib237","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","article-title":"A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book","volume":"55","author":"Mishara","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib238","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/ajp.2007.164.4.630","article-title":"Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia","volume":"164","author":"Mizrahi","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib239","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopsych.2011.10.009","article-title":"Increased stress-induced dopamine release in psychosis","volume":"71","author":"Mizrahi","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.31887\/DCNS.2012.14.1\/smorris","article-title":"Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior","volume":"14","author":"Morris","year":"2012","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib241","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0278-5846(97)00179-6","article-title":"Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders","volume":"22","author":"Muller","year":"1998","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib242","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1073\/pnas.91.23.11271","article-title":"Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain","volume":"91","author":"Murray","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.107704_bib243","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nrn2253","article-title":"Cannabis, the mind and society: the hash realities","volume":"8","author":"Murray","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib244","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0165-1781(85)90108-8","article-title":"Neuroleptic withdrawal in chronic schizophrenia: CT and endocrine variables relating to psychopathology","volume":"16","author":"Naber","year":"1985","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib245","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00166-3","article-title":"Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs","volume":"50","author":"Naber","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib246","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib247","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1017\/S1461145710001343","article-title":"Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models","volume":"14","author":"Natesan","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib248","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0028-3908(95)00170-0","article-title":"Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors","volume":"35","author":"Newman-Tancredi","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib249","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2014a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2019.107704_bib250","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2015.2582","volume":"73","author":"Nielsen","year":"2016","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib251","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib252","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-199808000-00010","article-title":"Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients","volume":"18","author":"Nordstrom","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib253","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02251294","article-title":"High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET","volume":"110","author":"Nordstr\u00f6m","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib254","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients","volume":"33","author":"Nordstrom","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib255","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","article-title":"D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients","volume":"152","author":"Nordstrom","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib256","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/JCP.0b013e3181f14098","article-title":"Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the european schizophrenia outpatient health outcomes study","volume":"30","author":"Novick","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib257","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib258","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib259","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02251280","article-title":"5-HT 2 and D 2 dopamine receptor occupancy in the living human brain","volume":"110","author":"Nyberg","year":"1993","journal-title":"Psychopharmacology"},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2019.107704_bib260","first-page":"81","article-title":"Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man","volume":"10","author":"Nyberg","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib261","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/385634a0","article-title":"Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET","volume":"385","author":"Okubo","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib262","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.bjp.0701357","article-title":"Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor","volume":"122","author":"Olianas","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2019.107704_bib263","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41380-018-0041-5","article-title":"Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures","volume":"24","author":"Osimo","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib264","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0140-6736(78)91740-3","article-title":"Increased dopamine-receptor sensitivity in schizophrenia","volume":"2","author":"Owen","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107704_bib265","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0091-3057(88)90120-7","article-title":"Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats","volume":"30","author":"Parada","year":"1988","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.107704_bib266","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2008.09.025","article-title":"Weight effects associated with antipsychotics: a comprehensive database analysis","volume":"110","author":"Parsons","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib267","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/0269881118776738","article-title":"Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation","volume":"32","author":"Patel","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib268","doi-asserted-by":"crossref","first-page":"15341","DOI":"10.1523\/JNEUROSCI.2747-09.2009","article-title":"Outwardly rectifying tonically active GABAA receptors in pyramidal cells modulate neuronal offset, not gain","volume":"29","author":"Pavlov","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib269","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/BF02245620","article-title":"Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects","volume":"124","author":"Peacock","year":"1996","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib270","article-title":"A meta-analysis of immune parameters, variability and assessment of modal distribution in psychosis and test of the immune sub-group hypothesis","author":"Pillinger","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib271","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1017\/S0033291700025575","article-title":"Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study","volume":"23","author":"Pilowsky","year":"1993","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2019.107704_bib272","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.mp.4001751","article-title":"First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients","volume":"11","author":"Pilowsky","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib273","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.biopsych.2018.02.1171","article-title":"Positron emission tomography studies of the glial cell marker translocator protein in patients with psychosis: a meta-analysis using individual participant data","volume":"84","author":"Plaven-Sigray","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib274","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1176\/appi.ajp.159.2.227","article-title":"A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography","volume":"159","author":"Potkin","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib275","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bdi.12707","article-title":"Second-generation antipsychotic long-acting injections in bipolar disorder: systematic review and meta-analysis","volume":"20","author":"Prajapati","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.neuropharm.2019.107704_bib276","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0920-9964(94)00034-6","article-title":"Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms","volume":"14","author":"Prell","year":"1995","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib277","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamapsychiatry.2015.2196","article-title":"Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis","volume":"72","author":"Radua","year":"2015","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib278","article-title":"Impaired prefrontal cortical dopamine release in schizophrenia during a cognitive task: a [11C]FLB 457 positron emission tomography study","author":"Rao","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib279","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bmj.39341.608519.BE","article-title":"Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine","volume":"335","author":"Raveendran","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2019.107704_bib280","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/JCP.0b013e31820e4818","article-title":"A double-blind, randomized, placebo-controlled study of the dopamine D(3) receptor antagonist ABT-925 in patients with acute schizophrenia","volume":"31","author":"Redden","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib281","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/schbul\/sbn044","article-title":"Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders","volume":"35","author":"Reichenberg","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib282","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0306-4522(94)90178-3","article-title":"Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current","volume":"59","author":"Reiner","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.107704_bib283","first-page":"1","article-title":"Neuroinflammation in schizophrenia","author":"Reis Marques","year":"2018","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2019.107704_bib284","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.91.24.11651","article-title":"Elevated dopa decarboxylase activity in living brain of patients with psychosis","volume":"91","author":"Reith","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.107704_bib285","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib286","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.107704_bib287","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/NMD.0000000000000295","article-title":"Ten-year outcomes of first-episode psychoses in the MRC \u00c6SOP-10 study","volume":"203","author":"Revier","year":"2015","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2019.107704_bib288","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(02)08913-4","article-title":"Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism","volume":"359","author":"Reynolds","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107704_bib289","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","article-title":"Dopamine and serotonin receptor binding and antipsychotic efficacy","volume":"32","author":"Richtand","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib290","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archpsyc.1975.01760230138011","article-title":"Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder","volume":"32","author":"Rifkin","year":"1975","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib291","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/jpet.115.225748","article-title":"A novel modulator of Kv3 potassium channels regulates the firing of parvalbumin-positive cortical interneurons","volume":"354","author":"Rosato-Siri","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib292","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/npp.2014.192","article-title":"Effects of the D 1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder","volume":"40","author":"Rosell","year":"2015","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib293","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0306-4530(80)90015-3","article-title":"The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations","volume":"5","author":"Rubin","year":"1980","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib294","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib295","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib296","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","article-title":"\u201cBreakthrough\u201d dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time","volume":"27","author":"Samaha","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib297","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1474-4422(18)30052-8","article-title":"Pimavanserin for patients with Alzheimer's disease psychosis","volume":"17","author":"Schneider","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib298","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0920-9964(95)00043-7","article-title":"Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia","volume":"19","author":"Schroder","year":"1996","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib299","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.euroneuro.2013.06.005","article-title":"Schizophrenia and dopamine receptors","volume":"23","author":"Seeman","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/cn400189s","article-title":"Clozapine, a fast-off-D2 antipsychotic","volume":"5","author":"Seeman","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib301","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.107704_bib302","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mp.4000336","article-title":"Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors","volume":"3","author":"Seeman","year":"1998","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib303","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib304","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib305","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41593-018-0334-7","article-title":"Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning","volume":"22","author":"Sellgren","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib306","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Selvaraj","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib307","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.124.3212.121","article-title":"Some serotoninlike activities of lysergic acid diethylamide","volume":"124","author":"Shaw","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.107704_bib308","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib309","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib310","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/S0021-9258(20)65148-1","article-title":"Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor","volume":"257","author":"Sibley","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.107704_bib311","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib312","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2019.107704_bib313","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-007-0727-x","article-title":"Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme","volume":"192","author":"Siuciak","year":"2007","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib314","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/syn.20734","article-title":"Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride","volume":"64","author":"Slifstein","year":"2010","journal-title":"Synapse (N. Y.)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib315","first-page":"1","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia","volume":"10032","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib316","first-page":"1","article-title":"Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder","author":"Solmi","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib317","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/DDDT.S133205","article-title":"Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solmi","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib318","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib319","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/cne.24337","article-title":"GABAA receptor subunits in the human amygdala and hippocampus: immunohistochemical distribution of 7 subunits","volume":"526","author":"Stefanits","year":"2018","journal-title":"J. Comp. Neurol."},{"issue":"7","key":"10.1016\/j.neuropharm.2019.107704_bib320","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ijnp\/pyz017","article-title":"D1-Dopamine receptor availability in first-episode neuroleptic naive psychosis patients","volume":"22","author":"Stenkrona","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib321","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2017.06.024","article-title":"Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder","volume":"193","author":"Stiekema","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib322","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neuroimage.2014.05.035","article-title":"Acute increases in synaptic GABA detectable in the living human brain: a [11C]Ro15-4513 PET study","volume":"99","author":"Stokes","year":"2014","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2019.107704_bib323","series-title":"Cortical Dopamine D(2)\/D(3) Receptors Are a Common Site of Action for Antipsychotic Drugs\u2014An Original Patient Data Meta-Analysis of the SPECT and PET in Vivo Receptor Imaging Literature. Schizophr Bull","first-page":"789","author":"Stone","year":"2009"},{"key":"10.1016\/j.neuropharm.2019.107704_bib324","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","article-title":"Results of phase 3 of the CATIE schizophrenia trial","volume":"107","author":"Stroup","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib325","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0306-4522(91)90277-U","article-title":"Presynaptic autoinhibition of the electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry","volume":"45","author":"Suaud-Chagny","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.107704_bib326","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(94)90718-8","article-title":"Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors","volume":"263","author":"Svensson","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib327","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2125.2001.01471.x","article-title":"Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine","volume":"52","author":"Tagawa","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib328","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1126\/science.347574","article-title":"Schizophrenic symptoms improve with apomorphine","volume":"200","author":"Tamminga","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.107704_bib329","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbx022.095","article-title":"M100. AMPA receptor subunit expression and receptor binding in patients with schizophrenia: a systematic review of postmortem studies","volume":"43","author":"Tani","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.107704_bib330","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1176\/appi.ajp.161.9.1620","article-title":"Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics","volume":"161","author":"Tauscher","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib331","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib332","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.25107","article-title":"Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis","volume":"27","author":"Teo","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107704_bib333","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib334","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.pnpbp.2003.10.004","article-title":"Neurons expressing calcium-binding proteins in the prefrontal cortex in schizophrenia","volume":"28","author":"Tooney","year":"2004","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib335","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib336","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ntr\/nty034","article-title":"Alpha7 nicotinic receptors as therapeutic targets in schizophrenia","volume":"21","author":"Tregellas","year":"2018","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib337","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/mp.2016.90","article-title":"Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review","volume":"21","author":"Tr\u00e9panier","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib338","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib339","article-title":"Glutamate hypothesis in schizophrenia","volume":"0","author":"Uno","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107704_bib340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2017.12.019","article-title":"Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults","volume":"131","author":"Van Duinen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib341","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","article-title":"Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine","volume":"350","author":"Van Tol","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib342","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s00213-018-4916-6","article-title":"The role of striatal dopamine D2\/3 receptors in cognitive performance in drug-free patients with schizophrenia","volume":"235","author":"Veselinovic","year":"2018","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib343","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0028-3908(01)00063-6","article-title":"Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors","volume":"41","author":"Vickers","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107704_bib344","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/archpsyc.57.3.237","article-title":"Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia","volume":"57","author":"Volk","year":"2000","journal-title":"Arch. Gen. Psychiatr."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2019.107704_bib345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2016.03.001","article-title":"Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia","volume":"177","author":"Volk","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib346","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1017\/S0033291716001446","article-title":"Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders","volume":"46","author":"Volk","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2019.107704_bib347","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-003-1648-y","article-title":"Neuroleptic dysphoria: towards a new synthesis","volume":"171","author":"Voruganti","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2019.107704_bib348","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0091-3057(94)90152-X","article-title":"Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat","volume":"47","author":"Wadenberg","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.107704_bib349","first-page":"83","article-title":"Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain","volume":"4","author":"Wallace","year":"2011","journal-title":"Pharmacogenomics Personalized Med."},{"key":"10.1016\/j.neuropharm.2019.107704_bib350","first-page":"CD004028","article-title":"Valproate for schizophrenia","volume":"11","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.107704_bib351","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4155\/fmc.15.4","article-title":"AMPA receptor-positive allosteric modulators for the treatment of schizophrenia: an overview of recent patent applications","volume":"7","author":"Ward","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.107704_bib352","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-specific dopamine abnormalities in schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib353","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/mp.2017.107","article-title":"PET imaging of dopamine-D2 receptor internalization in schizophrenia","volume":"23","author":"Weinstein","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib354","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0006-3223(02)01541-X","article-title":"Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia","volume":"53","author":"Weiss","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib355","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/35069076","article-title":"Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses","volume":"410","author":"Wilson","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107704_bib356","first-page":"959","article-title":"Negative symptoms and hypofrontality in chronic schizophrenia","volume":"49","author":"Wolkin","year":"1992","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107704_bib357","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1176\/ajp.154.7.1013","article-title":"Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons","volume":"154","author":"Woo","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib358","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib359","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1085\/jgp.201711980","article-title":"The ins and outs of vesicular monoamine transporters","volume":"150","author":"Yaffe","year":"2018","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib360","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.pnpbp.2004.05.033","article-title":"Proposal for a noradrenaline hypothesis of schizophrenia","volume":"28","author":"Yamamoto","year":"2004","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107704_bib361","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2006.06.008","article-title":"The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies","volume":"113","author":"Yanai","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.107704_bib362","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology : Off. Publ. Am. Coll. Neuropsychopharmacol.y"},{"key":"10.1016\/j.neuropharm.2019.107704_bib363","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib364","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0920-9964(98)00041-3","article-title":"Dopamine D2 densities and the schizophrenic brain","volume":"32","author":"Zakzanis","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107704_bib365","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0014-2999(96)00956-9","article-title":"Muscarinic m4 receptor activation by some atypical antipsychotic drugs","volume":"321","author":"Zeng","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib366","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0014-2999(84)90509-0","article-title":"Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis","volume":"97","author":"Zetterstr\u00f6m","year":"1984","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107704_bib367","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.euroneuro.2017.11.007","article-title":"Adjunctive azapirone for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"28","author":"Zheng","year":"2018","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081930262X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081930262X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:02:26Z","timestamp":1758438146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081930262X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":367,"alternative-id":["S002839081930262X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107704","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107704"}}